164 related articles for article (PubMed ID: 32027253)
21. Pathogenic Function of Herpesvirus Entry Mediator in Experimental Autoimmune Uveitis by Induction of Th1- and Th17-Type T Cell Responses.
Sakoda Y; Nagai T; Murata S; Mizuno Y; Kurosawa H; Shoda H; Morishige N; Yanai R; Sonoda KH; Tamada K
J Immunol; 2016 Apr; 196(7):2947-54. PubMed ID: 26912321
[TBL] [Abstract][Full Text] [Related]
22. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
Cheung TC
Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
[TBL] [Abstract][Full Text] [Related]
23. Unconventional ligand activation of herpesvirus entry mediator signals cell survival.
Cheung TC; Steinberg MW; Oborne LM; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6244-9. PubMed ID: 19332782
[TBL] [Abstract][Full Text] [Related]
24. Role of B and T Lymphocyte Attenuator in Renal Transplant Recipients with Biopsy-Proven Acute Rejection.
Wang Z; Yang H; Liu X; Zhang J; Han Z; Tao J; Zhao C; Ju X; Tan R; Gu M
Med Sci Monit; 2018 Jan; 24():387-396. PubMed ID: 29352109
[TBL] [Abstract][Full Text] [Related]
25. The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis.
Mintz MA; Felce JH; Chou MY; Mayya V; Xu Y; Shui JW; An J; Li Z; Marson A; Okada T; Ware CF; Kronenberg M; Dustin ML; Cyster JG
Immunity; 2019 Aug; 51(2):310-323.e7. PubMed ID: 31204070
[TBL] [Abstract][Full Text] [Related]
26. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
Murphy TL; Murphy KM
Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
[TBL] [Abstract][Full Text] [Related]
27. Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies.
Kuncewicz K; Battin C; Sieradzan A; Karczyńska A; Orlikowska M; Wardowska A; Pikuła M; Steinberger P; Rodziewicz-Motowidło S; Spodzieja M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238640
[TBL] [Abstract][Full Text] [Related]
28. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
[TBL] [Abstract][Full Text] [Related]
29. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
30. Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.
Bai Y; Shi Y; Li Y; Cai B; Zou Y; Wang L
Transpl Immunol; 2013 Jan; 28(1):38-47. PubMed ID: 23165214
[TBL] [Abstract][Full Text] [Related]
31. Structural determinants of herpesvirus entry mediator recognition by murine B and T lymphocyte attenuator.
Nelson CA; Fremont MD; Sedy JR; Norris PS; Ware CF; Murphy KM; Fremont DH
J Immunol; 2008 Jan; 180(2):940-7. PubMed ID: 18178834
[TBL] [Abstract][Full Text] [Related]
32. Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex.
Compaan DM; Gonzalez LC; Tom I; Loyet KM; Eaton D; Hymowitz SG
J Biol Chem; 2005 Nov; 280(47):39553-61. PubMed ID: 16169851
[TBL] [Abstract][Full Text] [Related]
33. The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.
Guruprasad P; Carturan A; Zhang Y; Cho JH; Kumashie KG; Patel RP; Kim KH; Lee JS; Lee Y; Kim JH; Chung J; Joshi A; Cohen I; Shestov M; Ghilardi G; Harris J; Pajarillo R; Angelos M; Lee YG; Liu S; Rodriguez J; Wang M; Ballard HJ; Gupta A; Ugwuanyi OH; Hong SJA; Bochi-Layec AC; Sauter CT; Chen L; Paruzzo L; Kammerman S; Shestova O; Liu D; Vella LA; Schuster SJ; Svoboda J; Porazzi P; Ruella M
Nat Immunol; 2024 Jun; 25(6):1020-1032. PubMed ID: 38831106
[TBL] [Abstract][Full Text] [Related]
34. A crucial role for HVEM and BTLA in preventing intestinal inflammation.
Steinberg MW; Turovskaya O; Shaikh RB; Kim G; McCole DF; Pfeffer K; Murphy KM; Ware CF; Kronenberg M
J Exp Med; 2008 Jun; 205(6):1463-76. PubMed ID: 18519647
[TBL] [Abstract][Full Text] [Related]
35. Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma.
Wojciechowicz K; Kuncewicz K; Rutkowski J; Jassem J; Rodziewicz-Motowidło S; Wardowska A; Spodzieja M
Biomed Pharmacother; 2024 Jun; 175():116675. PubMed ID: 38733770
[TBL] [Abstract][Full Text] [Related]
36. The role of the BTLA-HVEM complex in the pathogenesis of breast cancer.
Hu X
Breast Cancer; 2024 May; 31(3):358-370. PubMed ID: 38483699
[TBL] [Abstract][Full Text] [Related]
37. BTLA-HVEM Checkpoint Axis Regulates Hepatic Homeostasis and Inflammation in a ConA-Induced Hepatitis Model in Zebrafish.
Shi W; Shao T; Li JY; Fan DD; Lin AF; Xiang LX; Shao JZ
J Immunol; 2019 Nov; 203(9):2425-2442. PubMed ID: 31562209
[TBL] [Abstract][Full Text] [Related]
38. T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines.
Kim Y; Kim JE; Lee DY; Choi JU; Park JS; Lee HK; Choi SU; Park S; Park CH
Anticancer Res; 2023 Aug; 43(8):3419-3427. PubMed ID: 37500142
[TBL] [Abstract][Full Text] [Related]
39. The BTLA-HVEM complex - The future of cancer immunotherapy.
Wojciechowicz K; Spodzieja M; Wardowska A
Eur J Med Chem; 2024 Mar; 268():116231. PubMed ID: 38387336
[TBL] [Abstract][Full Text] [Related]
40. The Expression of BTLA Was Increased and the Expression of HVEM and LIGHT Were Decreased in the T Cells of Patients with Rheumatoid Arthritis [corrected].
Yang B; Huang Z; Feng W; Wei W; Zhang J; Liao Y; Li L; Liu X; Wu Z; Cai B; Bai Y; Wang L
PLoS One; 2016; 11(5):e0155345. PubMed ID: 27183113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
